REDDING, Calif., Dec. 7, 2022 /PRNewswire/ — According to a new market research report titled, ‘Artificial Intelligence in Genomics Market by Offering (Software, Services), Functionality (Sequencing, Gene Editing), Application (Diagnostics, Precision Medicine, Drug Discovery and Development), Delivery Mode (On-premise, Cloud) and End User – Global Forecast to 2029, ” published by Meticulous Research®, the global AI in genomics market is expected to reach $6.22 billion by 2029 at a CAGR of 42.8% during the forecast period 2022–2029.
Download Free Report Sample Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5345
The application of artificial intelligence (AI) or machine learning has been widely increasing in genomics studies, requiring production of complex and large amounts of data. The integration of AI has been used in the discovery of cell morphology and spatial organization, prediction of DNA regulatory regions, cancer diagnosis, and identification of associations between phenotypes and genotypes. Drug discovery and precision medicine are the areas in pharmaceuticals largely impacted by the integration of AI in genomics. To accelerate precision medicine, AI is being used to convert genomic data into actionable clinical information.
In addition to accelerated drug discovery and precision medicines, technological advancements in AI capabilities in genomics and rising funding for genomics studies are driving the global AI in genomics market. Additionally, improving infrastructure for AI and genomics research in emerging economies offers market growth opportunities. However, ambiguous regulatory guidelines for genomics software and poor security & storage of large volumes of genome sequencing data pose a challenge for the market.
The artificial intelligence in genomics market is segmented by offering (software, services), delivery mode (on-premises, cloud & web-based), functionality (genome sequencing, gene editing, other functionalities), application (drug discovery and development, precision medicine, diagnostics, and other applications), end user (pharmaceutical & biopharmaceutical companies, academic & research institutes, and other end users), and geography. The study also evaluates industry competitors and analyzes their market shares at global and regional levels.
Speak to our Analysts to Understand the Impact of COVID-19 on Your Business: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5345
Based on offering, in 2022, the software segment is estimated to account for the largest share of the global AI in genomics market. Software is the set of data or programs and instructions used to operate specific tasks. AI genomic software plays an important role in drug discovery, precision medicine, and diagnostics. The market players offer AI in genomics software-as-a-service, license-based, or subscription-based, which generates more revenue due to repeat purchases. The prices of these software offerings are high compared to the prices of services. Thus, the revenue generated by software is more compared to the services.
Based on delivery mode, the cloud & web-based segment is estimated to register the highest CAGR during the forecast period. The cloud & web-based models provide easy accessibility and increased scalability at lower costs. Furthermore, using cloud-based models, researchers can securely store, process, explore, and share large genomic datasets.
Based on functionality, in 2022, the genome sequencing segment is estimated to account for the largest share of the global AI in genomics market. The increasing adoption of AI in genome sequencing studies and the growing implementation of COVID-19-related R&D are contributing to the large market share of this segment. For instance, in January 2022, a research initiative led by scientists at Stanford University (U.S.), NVIDIA Corporation (U.S.), Oxford Nanopore Technologies Limited (U.K.), Google (U.S.), University of California (U.S.), and Baylor College of Medicine (U.S.) entered the Guinness World Record for fastest DNA sequencing technique using AI. The researchers used AI for sequencing a human genome in 5 hours and 2 minutes to ultimately use the findings in the diagnosis of rare genetic diseases in an average of eight hours.
Based on application, in 2022, the drug discovery and development segment is estimated to account for the largest share of the global AI in genomics market. The growing adoption of AI algorithms for drug discovery and rising collaboration between pharmaceutical/biopharmaceutical companies and AI solutions provider companies are driving the market.
Quick Buy – Artificial Intelligence in Genomics Market – Global Opportunity Analysis And Industry Forecast (2022-2029), Research Report: https://www.meticulousresearch.com/Checkout/54335299
Based on end user, in 2022, the pharmaceutical & biopharmaceutical companies segment is estimated to account for the largest share of the global AI in genomics market. The adoption of AI in genomics is relatively high in drug discovery and development and precision medicine compared to diagnostics or animal health. Pharmaceutical & biopharmaceutical companies use AI algorithms to speed up the process of drug discovery. Thus, pharmaceutical & biopharmaceutical companies are the highest revenue contributors to the market.
Based on geography, the artificial intelligence in genomics market is segmented into five major regions: North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, with a further analysis of major countries in these regions. In 2022, North America is estimated to account for the largest share of the global AI in genomics market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The key factors contributing to the large market share of this segment are the availability of infrastructure for genomic research and AI, the presence of key players in this region, and increasing research initiatives in genomics.
Some of the key players operating in the AI in genomics market are Microsoft Corporation (U.S.), NVIDIA Corporation (U.S.), Deep Genomics Incorporated (Canada), Fabric Genomics, Inc. (U.S.), Data4Cure, Inc. (U.S.), Predictive Oncology Inc. (U.S.), Emedgene Technologies LTD (U.S.), Congenica Ltd. (U.K.), Tempus Labs, Inc. (U.S.), SOPHiA GENETICS SA (Switzerland), Illumina Inc. (U.S.), and BenevolentAI Limited. (U.K.).
To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/ai-in-genomics-market-5345
Scope of the Report:
Artificial Intelligence in Genomics Market, by Offering
Software
Services
Artificial Intelligence in Genomics Market, by Delivery Mode
On-premises
Cloud & Web-based
Artificial Intelligence in Genomics Market, by Functionality
Genome Sequencing
Gene Editing
Other Functionalities
Note: Other functionalities include pharmacogenomics and predictive gene testing.
Artificial Intelligence in Genomics Market, by Application
Drug Discovery & Development
Precision Medicine
Diagnostics
Other Applications
Note: Other applications include agriculture, pharmacology, and animal health.
Artificial Intelligence in Genomics Market, by End User
Pharmaceutical & Biopharmaceutical Companies
Academic & Research Institutes
Other End Users
Note: Other end users include contract research organizations and agriculture companies.
Artificial Intelligence in Genomics Market, by Geography
North America
Europe
Asia-Pacific (APAC)
Latin America
Middle East & Africa
Download Free Report Sample Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5345
Related Reports:
Healthcare Artificial Intelligence Market by Product and Services (Software, Services), Technology (Machine Learning, NLP), Application (Medical Imaging, Precision Medicine, Patient Management), End User (Hospitals, Patients) – Global Forecast to 2027
https://www.meticulousresearch.com/product/healthcare-artificial-intelligence-market-4937
Artificial Intelligence in Cybersecurity Market by Technology (ML, NLP), Security (Endpoint, Cloud, Network), Application (DLP, UTM, IAM, Antivirus, IDP), Industry (Retail, Government, BFSI, IT, Healthcare), and Region – Global Forecasts to 2029
https://www.meticulousresearch.com/product/artificial-intelligence-in-cybersecurity-market-5101
Artificial Intelligence in Manufacturing Market By Component, Technology (ML, NLP, Computer Vision), Application (Predictive Maintenance Quality Management, Supply Chain, Production Planning), Industry Vertical, & Geography – Global Forecast to 2028
https://www.meticulousresearch.com/product/artificial-intelligence-in-manufacturing-market-4983
Artificial Intelligence in Retail Market by Product, Application (Predictive Merchandizing, Programmatic Advertising), Technology (Machine Learning, Natural Language Processing), Deployment (Cloud, On-Premises), and Geography – Global Forecast to 2027
https://www.meticulousresearch.com/product/artificial-intelligence-in-retail-market-4979
About Meticulous Research®
Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.
Contact:
Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe: +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Content Source: https://www.meticulousresearch.com/pressrelease/571/artificial-intelligence-in-genomics-market-2029
Logo: https://mma.prnewswire.com/media/1757980/Meticulous_Research_Logo_1.jpg
View original content:https://www.prnewswire.com/news-releases/artificial-intelligence-in-genomics-market-to-reach-6-22-billion-by-2029—exclusive-report-by-meticulous-research-301697077.html
SOURCE Meticulous Market Research Pvt. Ltd.
Yahoo Finance Live's Seana Smith breaks down the stocks trending in the after-hours trading session.
Is it time to bet on a turnaround?
Wake up and smell the diesel.
After falling for much of the week, the major stock market indexes were gaining ground early Thursday as investors digested the latest unemployment numbers. Last week's initial jobless claims suggest the Federal Reserve's campaign to combat inflation may finally be bearing fruit. Investors used that positive development as an excuse to buy up their favorite beaten-down tech stocks.
In this article, we will discuss the 15 best electric car stocks to buy now. If you want to explore similar stocks, you can also take a look at 5 Best Electric Car Stocks To Buy Now. The Electric Car Industry: An Analysis Electric car stocks are increasingly becoming a popular investment option as the […]
Media reports suggest that Hong Kong could relax certain restrictions aimed at preventing the spread of COVID-19.
In this article, we will discuss the 14 Best Marijuana Stocks To Buy Now. You can skip our detailed industry analysis and go directly to the 5 Best Marijuana Stocks To Buy Now. The cannabis industry is expected to undergo rapid changes in the coming years. One reason is the increasing awareness of the health benefits […]
At age 51, Anne Schieber was broke and disillusioned. She had worked for the IRS for 23 years and was regarded as one of the agency’s top auditors. But she never got promoted and never earned more than $3,150 in a year. With half her life already behind her, her retirement prospects looked bleak. But Schieber had learned a powerful secret from years of studying the tax returns of America’s richest residents. Over the next 50 years, it earned her a 449,000% return — making Schieber one of the mos
Earlier this year, in May, claims were made that Microsoft Corp co-founder Bill Gates owned the majority of America’s farmland. While that is false, with the billionaire amassing nearly 270,000 acres of farmland across the country, compared to 900 million total farm acres, a different billionaire privately owns 2.2 million acres, making him the largest landowner in the U.S. John Malone, the former CEO of Tele-Communications Inc., which AT&T Inc. purchased for more than $50 billion in 1999, has a
Investors searching for that feeling telling you market sentiment is shifting to a more positive outlook have been brought down to earth again. Following 2022’s market behavior to a tee, the recent rally has run into a brick wall. To wit, the S&P 500 notched 5 consecutive negative sessions over the last week with investors mulling over the prospect of a recession. Indeed, financial experts have been sounding the warning bells on the precarious state of the global economy. One of the doomsayers h
Shares of Boeing (NYSE: BA) were up more than 4% as of 10 a.m. ET today. Bank of America's Ron Epstein raised his price target to $190 from $165, Citibank analyst Jason Gursky initiated his coverage with a buy rating, and Wells Fargo analyst Matthew Akers raised his price target to $218 from $185. The price target hikes and buy recommendations are supported by an improving environment for Boeing Commercial Airplanes (BCA).
L1 Capital International, an investment management company, released its “L1 Capital International Fund” third-quarter 2022 investor letter. A copy of the same can be downloaded here. The fund returned -0.4% net of fees in the third quarter compared to a 0.3% return for the MSCI World Net Total Return Index in AUD. The depreciation of Australian […]
In this article, we will be taking a look at the 22 most indebted companies in the world in 2022. To skip our detailed analysis, you can go directly to see 5 Most Indebted Companies in the World in 2022. When companies want to raise cash for their businesses, there are two main ways to […]
Buy and hold forever? Not always.
Shares of Summit Therapeutics (NASDAQ: SMMT) were skyrocketing 371.8% higher this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence. This huge gain came after the company announced on Tuesday that it's licensing bispecific antibody ivonescimab from Chinese drugmaker Akeso. Akeso will retain the rights to market the therapy throughout the rest of the world, including China.
Whilst it may not be a huge deal, we thought it was good to see that the New York Community Bancorp, Inc. ( NYSE:NYCB…
General Electric’s healthcare division plans to cut debt, bring down costs and pursue tuck-in acquisitions after its spinoff in early January, finance chief Helmut Zodl said Thursday at an investor event in New York.
Shares of Algonquin Power & Utilities (NYSE: AQN) crashed 31.7% in November, according to data provided by S&P Global Market Intelligence. It turned out to be the worst month for the utility stock in 2022 so far, with Algonquin shares now tumbling a whopping 49% year to date as of this writing. Utility stocks typically carry large amounts of debt and have, therefore, taken a beating this year amid rising interest rates.
Costco's first quarter earnings missed Street forecasts following a pullback in sales over the final weeks of autumn.
Shares of Hello Group (NASDAQ: MOMO) were up 36% as of 9:31 a.m. ET on Thursday after the company reported better-than-expected earnings results for the third quarter. While management expects another decline in revenue next quarter, the sequential improvement in earnings per share is all that matters right now.
Leave a Reply
You must be logged in to post a comment.